Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure

NCT00658437 is registered in ClinicalTrials.gov with Cytavis Biopharma GmbH as lead sponsor.

NCT NCT00658437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00658437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure
Lead sponsor
Cytavis Biopharma GmbH
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
May 31, 2010
Enrollment
31 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma